Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
AssigneeGlycArt Biotechnology AG
InventorsPablo Umana, Ekkehard Mossner
Life of this patent
Estimating the term…
Loading patent…
AssigneeGlycArt Biotechnology AG
InventorsPablo Umana, Ekkehard Mossner
Estimating the term…
The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human MCSP. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.
An isolated polynucleotide comprising:
An isolated polynucleotide comprising
An isolated polynucleotide comprising a sequence selected from the group consisting of:
5-7. (canceled)
An isolated polynucleotide comprising a sequence selected from the group consisting of SEQ ID No:29, SEQ ID No:31, and SEQ ID No:33;
(canceled)
(canceled)
An isolated polynucleotide comprising a sequence having at least 80% identity to a sequence selected from the group consisting of:
An isolated polynucleotide comprising a sequence having at least 80% identity to a sequence selected from the group consisting of:
14-23. (canceled)
An isolated polynucleotide encoding a polypeptide having a sequence selected from the group consisting of SEQ ID No:4;
An isolated polynucleotide encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:30, SEQ ID NO:32;
27-30. (canceled)
32-34. (canceled)
A fusion polypeptide comprising a sequence selected from the group consisting of SEQ ID No:2;
A fusion polypeptide comprising a sequence selected from the group consisting of:
38-39. (canceled)
41-48. (canceled)
51-53. (canceled)
55-56. (canceled)
58-65. (canceled)
67-69. (canceled)
71-72. (canceled)
(canceled)
76-77. (canceled)
(canceled)
81-108. (canceled)
An isolated polynucleotide comprising at least one complementarity determining region of the murine 225.28S monoclonal antibody, or a variant or truncated form thereof containing at least the specificity-determining residues for said complementarity determining region, wherein said isolated polynucleotide encodes a fusion polypeptide.
112-115. (canceled)
117-120. (canceled)
A method for producing an antigen binding molecule having modified oligosaccharides in a host cell, said method comprising:
123-124. (canceled)
126-127. (canceled)
129-130. (canceled)
(canceled)
(canceled)
136-144. (canceled)
148-151. (canceled)
153-157. (canceled)
(canceled)
161-174. (canceled)
178-181. (canceled)
185-191. (canceled)
Dependencies are inferred from the claim text.